TY - JOUR
T1 - Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals
AU - Ainsua-Enrich, Erola
AU - Pedreño-Lopez, Núria
AU - Bracke, Carmen
AU - Avila-Nieto, Carlos
AU - Rodríguez de la Concepción, María Luisa
AU - Pradenas, Edwards
AU - Trinité, Benjamin
AU - Marfil, Silvia
AU - Miranda, Cristina
AU - González, Sandra
AU - Toledo, Ruth
AU - Font, Marta
AU - Benet, Susana
AU - Escribà, Tuixent
AU - Jimenez-Moyano, Esther
AU - Peña, Ruth
AU - Cedeño, Samandhy
AU - Prado, Julia G.
AU - Mothe, Beatriz
AU - Brander, Christian
AU - Izquierdo Useros, Nuria
AU - Vergara-Alert, Júlia
AU - Segalés Coma, Joaquim
AU - Massanella, Marta
AU - Benítez Díaz, Rosa María
AU - Romero, Alba
AU - Molina-Morant, Daniel
AU - Blanco, Julià
AU - Clotet Sala, Bonaventura
AU - Mateu, Lourdes
AU - Pedro-Botet, María Luisa
AU - Carrillo, Jorge
PY - 2022
Y1 - 2022
N2 - Mass vaccination campaigns reduced COVID-19 incidence and severity. Here, we evaluated the immune responses developed in SARS-CoV-2-uninfected patients with predominantly antibody-deficiencies (PAD) after three mRNA-1273 vaccine doses. PAD patients were classified based on their immunodeficiency: unclassified primary antibody-deficiency (unPAD, n=9), common variable immunodeficiency (CVID, n=12), combined immunodeficiency (CID, n=1), and thymoma with immunodeficiency (TID, n=1). unPAD patients and healthy controls (HCs, n=10) developed similar vaccine-induced humoral responses after two doses. However, CVID patients showed reduced binding and neutralizing titers compared to HCs. Interestingly, these PAD groups showed lower levels of Spike-specific IFN-γ-producing cells. CVID individuals also presented diminished CD8+ T cells. CID and TID patients developed cellular but not humoral responses. While the third vaccine dose boosted humoral responses in most PAD patients, it had limited effect on expanding cellular immunity. Vaccine-induced immune responses in PAD individuals are heterogeneous, and should be immunomonitored to define a personalized therapeutic strategies.
AB - Mass vaccination campaigns reduced COVID-19 incidence and severity. Here, we evaluated the immune responses developed in SARS-CoV-2-uninfected patients with predominantly antibody-deficiencies (PAD) after three mRNA-1273 vaccine doses. PAD patients were classified based on their immunodeficiency: unclassified primary antibody-deficiency (unPAD, n=9), common variable immunodeficiency (CVID, n=12), combined immunodeficiency (CID, n=1), and thymoma with immunodeficiency (TID, n=1). unPAD patients and healthy controls (HCs, n=10) developed similar vaccine-induced humoral responses after two doses. However, CVID patients showed reduced binding and neutralizing titers compared to HCs. Interestingly, these PAD groups showed lower levels of Spike-specific IFN-γ-producing cells. CVID individuals also presented diminished CD8+ T cells. CID and TID patients developed cellular but not humoral responses. While the third vaccine dose boosted humoral responses in most PAD patients, it had limited effect on expanding cellular immunity. Vaccine-induced immune responses in PAD individuals are heterogeneous, and should be immunomonitored to define a personalized therapeutic strategies.
KW - Immune response
KW - Immunology
KW - Virology
U2 - 10.1016/j.isci.2022.105455
DO - 10.1016/j.isci.2022.105455
M3 - Article
C2 - 36320330
SN - 2589-0042
JO - iScience
JF - iScience
ER -
